Novo Nordisk has announced that it will be offering its obesity drug Wegovy directly to patients at a reduced price through its new direct-to-consumer offering called NovoCare Pharmacy. This move comes as the pharmaceutical company aims to compete for market share and draw patients away from compounding pharmacies that have been making cheaper copies of weight loss drugs.
Typically, Wegovy carries a list price of around $1,350 per month. However, Novo Nordisk will now sell the treatment for $499 a month for all doses to cash-paying patients, meaning those who are paying out of pocket without insurance. Orders will be fulfilled by CenterWell Pharmacy, a subsidiary of Humana that offers home delivery services.
This decision by Novo Nordisk comes in response to a similar move by Eli Lilly, as both drugmakers look to capture a larger share of the obesity drug market. By offering Wegovy at a reduced price directly to patients, Novo Nordisk hopes to make the treatment more accessible and affordable for those in need of weight loss medication.
The direct-to-consumer model not only benefits patients by offering a more affordable option but also allows Novo Nordisk to bypass traditional distribution channels and reach consumers directly. This strategy may help the company increase its market share and establish a stronger presence in the obesity drug market.
In conclusion, Novo Nordisk’s decision to sell Wegovy directly to patients at a reduced price through NovoCare Pharmacy is a strategic move to compete with other drugmakers and attract patients away from compounding pharmacies. By offering the treatment at a more affordable price, the company aims to make weight loss medication more accessible to those in need. This direct-to-consumer approach may prove to be successful in expanding Novo Nordisk’s reach and market share in the obesity drug market.
